SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first ...

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating ...

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a ...

The palbociclib-fulvestrant combination has been available on the NHS for certain breast cancer patients since 2022. The ...

Patients included in the trial had HR+/HER2– metastatic breast cancer, were 18 years or older, and started index treatment ...

New research indicates that a drug called Inavolisib is effective at treating a type of metastatic breast cancer with a ...

Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib ...

Giving women palbociclib – already hailed as a major step forward in treating advanced breast cancer – alongside hormone therapy had a much greater effect on cell growth than the hormone treatment ...